Drug development is well known to be a ‘high risk’ business, with many developments being stopped due to a variety of reasons. If patients get unacceptable side effects with the risks being bigger than the benefits, then it is reasonable to stop development on good ethical and business grounds.
However, the shocking truth is that up to 50% of Phase III clinical trials fail to show a separation from placebo. A further 15% fail to show a superior improvement in the primary end point(s) chosen.
Let’s just think about that. Read more